Olympus reviewed the following literature titled, "modified cap-assisted endoscopic mucosal resection versus endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors #10 mm: a randomized noninferiority tria".Introduction: although recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (net) =10 mm, there is no consensus on which endoscopic modality should be performed.We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (memr-c) and endoscopic submucosal dissection (esd) methods for the treatment of rectal net =10 mm.Methods: a randomized noninferiority trial comparing memr-c and esd was conducted.The primary outcome was the histological complete resection rate; the secondary outcomes included en bloc resection rate, operation time, complications, and so on.Subgroup analyses and follow-up were also performed.Results: ninety patients were enrolled, and 79 patients with pathologically confirmed rectal net were finally analyzed, including 38 cases of memr-c and 41 cases of esd.Histological complete resection rate was 97.4% in the memr-c group and 92.7% in the esd group.The noninferiority of memr-c compared with that of esd was confirmed because the absolute difference was 4.7% (2-sided 90% confidence interval, -3.3% to 12.2%; p = 0.616).En bloc resection and successful removal of rectal net were achieved in all patients.Advantages of memr-c over esd included shorter operation time (8.89 ± 4.58 vs 24.8 ± 9.14 minutes, p < 0.05) and lower hospitalization cost ($2,233.76 ± $717.70 vs $2,987.27 ± $871.81, p < 0.05).Postoperative complications were recorded in 4 patients who received memr-c and 2 patients in the esd group (11.5% vs 4.9%, p = 0.509), which were all well managed using endoscopy.Similar findings were observed when subgroup analysis was performed.Type of adverse events/number of patient: bleeding (n = 5).Perofration (n = 1).This literature article requires 2 reports.The related patient identifiers are as follows: (b)(6)(for mh-593).(b)(6)(for kd-655q).This medwatch report is for patient identifier (b)(6).There is no report of any olympus device malfunction in any procedure described in this study.
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation and correction to the initial with information inadvertently left out.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse events cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.Olympus will continue to monitor field performance for this device.
|